Loading...
Concert Pharmaceuticals, Inc.
CNCE•NASDAQ
HealthcareBiotechnology
$8.37
$0.00(0.00%)
Concert Pharmaceuticals, Inc. (CNCE) Company Profile & Overview
Explore Concert Pharmaceuticals, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Concert Pharmaceuticals, Inc. (CNCE) Company Profile & Overview
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
SectorHealthcare
IndustryBiotechnology
CEODr. Roger D. Tung Ph.D.
Contact Information
Company Facts
64 Employees
IPO DateFeb 13, 2014
CountryUS